Join us for the upcoming RMIP Research Spotlight featuring Dr. Johnny Huard from the Steadman Philippon Research Institute
RMIP Research Spotlight on Tuesday, June 17th at 3:00-4:00 PM ET:Register today!
Dr. Huard will be presenting the results from his phase I/II clinical study evaluating the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently or in combination, to improve the beneficial effect of bone marrow derived stem cells for improving outcomes in patients with knee osteoarthritis.
We hope that you will be able to join us for this spotlight.
Mike Enger
Join us for the upcoming RMIP Research Spotlight featuring Dr. Johnny Huard from the Steadman Philippon Research Institute
RMIP Research Spotlight on Tuesday, June 17th at 3:00-4:00 PM ET: Register today!
Dr. Huard will be presenting the results from his phase I/II clinical study evaluating the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently or in combination, to improve the beneficial effect of bone marrow derived stem cells for improving outcomes in patients with knee osteoarthritis.
We hope that you will be able to join us for this spotlight.